Raymond James analyst Jayson Bedford downgraded Edwards Lifesciences to Market Perform from Outperform without a price target. Raymond James is less confident in the sustainable growth profile, and says that recent recent TAVR trends continue in the 7%-8% range, limiting upside to estimates, the analyst tells investors in a research note. The firm believes that the narrative on the stock becomes more defensive until U.S. TAVR growth sustainably accelerates or the rich pipeline gets closer to commercialization.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences downgraded to Market Perform at Raymond James
- Early notable gainers among liquid option names on February 1st
- Edwards Lifesciences price target raised to $76 from $68 at Canaccord
- EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
- Edwards Lifesciences sees Q1 adjusted EPS 58c-64c, consensus 59c